Monthly Archives: May 2013

Only 12% of Public Biotechs are Profitable

Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both a product on the market and positive net income for FY 2012. This is about the same as the 13% reported last year, but different companies populate the list.  Unlike our last report (May 2012), when acquisitions of profitable companies Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Act Now to Protect Public Health and Prepare for the Upcoming Flu Season

Act Now to Protect Public Health and Prepare for the Upcoming Flu Season

As many as 49,000 people die from the flu annually, depending on the season, and children and the elderly are the most vulnerable. Among the 138 children who died from the flu during the 2012-2013 season, the Centers for Disease Control and Prevention (CDC) reports that 90 percent were not vaccinated.  In addition, more than 200,000 people are hospitalized, with the most vulnerable being infants, young children, older adults, and people of all ages who Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation.  The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical promise for serious or life-threatening conditions, thereby expediting both the development and the review of these drugs. As of today, 13 designations have been granted according to a search of the BioMedTracker database (see table Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Canada Patent Utility: Former USPTO Director Interview at BIO Convention

Photo credit to Meddy Garnet

David Kappos, former Director, US Patent and Trade Office and current Partner Cravath, Swaine and Moore, LLP discusses the Canadian Utility Requirement.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

“Time to Call out the Anti-GMO Conspiracy Theory”

Mark Lynas

In a speech last week at Cornell University on anti-GMO conspiracy theory, Mark Lynas told audiences “millions, possibly billions, of people have come to believe what is essentially a conspiracy theory, generating fear and misunderstanding about a whole class of technologies on an unprecedentedly global scale.” Formerly a devout anti-GMO activist himself, Lynas said his activism, “which I wrongly thought of at the time as being ‘environmental’, has done real damage in the world… I Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,